We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

Back to rankings

99 hedge funds and large institutions have $352M invested in Insys Therapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 39 increasing their positions, 26 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 26

0% more funds holding

Funds holding: 99 → 99 (0)

0% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 28

5% less capital invested

Capital invested by funds: $372M → $352M (-$20.2M)

39% less call options, than puts

Call options by funds: $2.61M | Put options by funds: $4.25M

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
99
Holders Change
–
Holders Change %
0%
% of All Funds
2.85%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.03%
New
28
Increased
39
Reduced
26
Closed
28
Calls
$2.61M
Puts
$4.25M
Net Calls
-$1.65M
Net Calls Change
-$4.32M

Top Buyers

Rank Fund Capital Flow
1
ECP
Empyrean Capital Partners
California
+$25.9M
2
BTP
Bloom Tree Partners
New York
+$25.4M
3
JHIU
Janus Henderson Investors US
Colorado
+$25.1M
4
CCM
Consonance Capital Management
New York
+$12.5M
5
BA
BlackRock Advisors
Delaware
+$8.26M

Top Sellers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
-$21M
2
TCM
Tamarack Capital Management
California
-$19.8M
3
Renaissance Technologies
Renaissance Technologies
New York
-$5.68M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$4.94M
5
Two Sigma Investments
Two Sigma Investments
New York
-$4.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
26
Opaleye Management
Massachusetts
$2.68M +$2.77M +171,600 New
GACM
27
Green Arrow Capital Management
New York
$2.63M +$2.72M +168,400 New
SFM
28
Systematic Financial Management
New Jersey
$2.55M -$8.95K -554 -0.3%
BIM
29
BlackRock Investment Management
Delaware
$2.38M +$1.12M +69,238 +83%
FAM
30
Foundation Asset Management
New York
$2.33M +$2.41M +149,190 New
PI
31
Putnam Investments
Massachusetts
$2.33M +$5.43K +336 +0.2%
KBC Group
32
KBC Group
Belgium
$2.26M +$2.34M +144,566 New
New York State Common Retirement Fund
33
New York State Common Retirement Fund
New York
$2.23M – – –
MWVC
34
Morgens Waterfall Vintiadis & Co
New York
$1.87M +$1.94M +120,000 New
American Century Companies
35
American Century Companies
Missouri
$1.81M +$1.87M +115,806 New
TI
36
Turner Investments
Pennsylvania
$1.74M +$1.8M +111,460 New
AI
37
Analytic Investors
California
$1.52M -$268K -16,566 -15%
JGC
38
J. Goldman & Co
New York
$1.5M +$1.56M +96,250 New
Geode Capital Management
39
Geode Capital Management
Massachusetts
$1.43M -$337K -20,842 -19%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$1.41M +$88.6K +5,482 +6%
GH
41
GAM Holding
Switzerland
$1.31M – – –
AQR Capital Management
42
AQR Capital Management
Connecticut
$1.23M +$9.7K +600 +0.8%
TCIM
43
TIAA CREF Investment Management
New York
$1.2M +$209K +12,904 +20%
AllianceBernstein
44
AllianceBernstein
Tennessee
$1.12M -$21M -1,300,564 -95%
Citadel Advisors
45
Citadel Advisors
Florida
$1.01M +$459K +28,370 +77%
GAM
46
Gotham Asset Management
New York
$940K +$424K +26,258 +77%
WMSA
47
Weiss Multi-Strategy Advisers
New York
$937K +$970K +60,000 New
HT
48
HAP Trading
New York
$835K -$106K -6,560 -11%
CAM
49
ClariVest Asset Management
California
$811K +$970 +60 +0.1%
ProShare Advisors
50
ProShare Advisors
Maryland
$801K -$217K -13,414 -21%
1
2
3 4 5

INSY Hedge Fund Activity: Q2 2014 in Review

99 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q2 2014, worth a combined $352M — down 5.4% from $372M a quarter earlier.

Fund positioning in INSY was balanced in Q2 2014: 28 funds opened new positions, 28 closed out, 39 added to existing stakes and 26 trimmed.

The largest buyer was Empyrean Capital Partners, opening a new position worth an estimated $25.9M. The largest seller was AllianceBernstein, cutting an estimated $21M.

  • 99 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q2 2014, unchanged from Q1 2014.
  • Funds reported $352M of Insys Therapeutics, Inc. stock for Q2 2014, down 5.4% quarter-over-quarter.
  • 28 funds opened new Insys Therapeutics, Inc. positions in Q2 2014 and 28 closed out, a net change of 0 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q2 2014 was Empyrean Capital Partners, an estimated $25.9M added.
  • The largest Insys Therapeutics, Inc. seller in Q2 2014 was AllianceBernstein, an estimated $21M sold.

Based on aggregated 13F filings for Q2 2014.